Results 121 to 130 of about 28,157 (212)

Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac

Vaccines
The SARS-CoV-2 Omicron variant and its sublineages continue to cause COVID-19-associated pediatric hospitalizations, severe disease, and death globally. BNT162b2 and CoronaVac are the main vaccines used in Chile.
Diego A. Díaz-Dinamarca, Simone Cárdenas-Cáceres, Nicolás A. Muena, Pablo Díaz, Gisselle Barra, Rodrigo Puentes, Daniel F. Escobar, Michal Díaz-Samirin, Natalia T. Santis-Alay, Cecilia Canales, Janepsy Díaz, Heriberto E. García-Escorza, Alba Grifoni, Alessandro Sette, Nicole D. Tischler, Abel E. Vasquez   +15 more
doaj   +1 more source

Supplementary Material for: COVID-19 Outbreaks in Nursing Homes Despite Full Vaccination with BNT162b2 of a Majority of Residents

, 2022
Carmelo Lafuente‐Lafuente, Antonio Rainone, Olivier Guérin, O. Drunat, Claude Jeandel, Olivier Hanon, Joël Belmin, for the C-VENH Investigators   +7 more
openalex   +1 more source

Age, Sex and BMI Relations with Anti-SARS-CoV-2-Spike IgG Antibodies after BNT162b2 COVID-19 Vaccine in Health Care Workers in Northern Greece [PDF]

, 2023
Paraskevi Papaioannidou, Kalypso Skoumpa, Christos Bostanitis, Maria Michailidou, Theodouli Stergiopoulou, Ioannis Bostanitis, Maria Tsalidou   +6 more
openalex   +1 more source

Supplementary Material for: Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients

, 2022
Yael Einbinder, Jeffrey Perl, Naomi Nacasch, Alon Bnaya, Linda Shavit, Daniel Erez, Moshe Shashar, T. Halperin, Ayelet Grupper, Sydney Benchetrit, Ori Wand, Keren Cohen‐Hagai   +11 more
openalex   +1 more source

Long-Term SARS-CoV-2-Specific Humoral and T Cell Responses after the BNT162b2 or BBIBP-CorV Booster and the Incidence of Breakthrough Infections among Healthcare Workers [PDF]

, 2023
Zsolt Matula, Gabriella Bekő, Viktória Király, Márton Gönczi, András Zóka, András Baráth, Ferenc Uher, István Vályi‐Nagy   +7 more
openalex   +1 more source

Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses [PDF]

, 2022
Victoria Hall, Victor H. Ferreira, Heidi Wood, Matthew Ierullo, Beata Majchrzak-Kita, Kathy Manguiat, Alyssia Robinson, Vathany Kulasingam, Atul Humar, Deepali Kumar   +9 more
openalex   +1 more source

BNT162b2 Covid-19 Vaccine in Adolescents

New England Journal of Medicine, 2021
openaire   +2 more sources

Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study [PDF]

, 2023
Metalia Puspitasari, Prenali Dwisthi Sattwika, Auliana R. P. Hidayat, Wynne Wijaya, Yulia Wardhani, Umi Solekhah Intansari, Nyoman Kertia, Bambang Purwanto, Jarir At Thobari   +8 more
openalex   +1 more source

Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine [PDF]

Neurological Sciences, 2021
Michele Trimboli, Pio Zoleo, Gennarina Arabia, Antonio Gambardella   +3 more
openaire   +2 more sources

Neurovascular Adverse Effects of Sars-Cov-2 Vaccination

Drug Design, Development and Therapy
Leonidas D Panos,1,2 Panagiotis Bargiotas,2 Georgios Hadjigeorgiou,2 Georgios D Panos3,4 1Department of Neurology, Bern University Hospital « Inselspital », Bern, Switzerland; 2Department of Neurology, School of Medicine, University of Cyprus, Nicosia ...
Panos LD, Bargiotas P, Hadjigeorgiou G, Panos GD   +3 more
doaj